David Russler-Germain, MD, PhD, of Washington University in St. Louis, Missouri, joins the hosts of “Blood Cancer Talks” to highlight research in lymphoma and chronic lymphocytic leukemia (CLL) presented at the 66th American Society of Hematology Annual Meeting & Exposition.
The episode focuses on the POLARIX trial of Pola-R-CHP in diffuse large B-cell lymphoma, the inMIND trial of tafasitamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma, the AMPLIFY trial of fixed-duration acalabrutinib plus venetoclax with or without obinutuzumab compared with chemoimmunotherapy in frontline CLL, and more.